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Abstract
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor for which no effective therapy
exists despite the discovery of many possible molecular and genetic targets. Many risk factors for
MPM development have been recognized including environmental exposures, genetic susceptibility,
viral contamination, and radiation. However, the late stage of MPM diagnosis and the long latency
that exists between some exposures and diagnosis have made it difficult to comprehensively
evaluate the role of risk factors and their downstream molecular effects. In this review, we discuss
the current molecular and genetic contributors in MPM pathogenesis and the risk factors
associated with these carcinogenic processes.
Introduction
Malignant pleural mesothelioma (MPM) is a solid, locally
aggressive tumor of the pleura that encases and invades
the lung parenchyma in late stages of the disease (see fig-
ure 1) causing clinically significant morbidities such as
dyspnea and chest pain [1,2]. Without treatment, MPM is
associated with a poor median survival, ranging from 4 to
12 months [2].
The single term MPM can be misleading in that these
tumors present with substantial phenotypic variability
and are, therefore, classified according to the relative pro-
portions of epithelial and spindle cells. The three major
histological types include epithelial (see figure 2), sarco-
matous (see figure 3), and mixed types. In all of these
types of malignant mesothelioma, the cells are more fre-
quently bi- or multi-nucleated, arranged in clumps, and
the nuclear and nucleolar sizes are proportionally larger
[3].
Epithelium-derived mesothelioma consists of large spher-
ical cells arranged in solid masses and columns that form
mainly within the lymphatics. These cells may also form
glandular structures that resemble adenocarcinoma (see
figure 2). The epithelial cells contain large numbers of
desmosomes, tonofilaments, and long, slender branching
microvilli that may have contact with extracellular colla-
gen because the basement membranes are incomplete
[4,5]. The sarcomatoid type originates from the deep con-
nective tissue of the mesothelium. These tumors are char-
acterized by ovoid-to-spindle-shaped cells similar to cells
seen in fibrosarcomas (see figure 3) [6]. Epithelial mes-
othelioma is the most prevalent type, followed by mixed/
biphasic, sarcomatous, and, rarely, desmoplastic types
[7]. In a large study, epithelial cell type was observed in
61.5% of specimens (n = 930), followed by biphasic in
22% (n = 334) and sarcomatous in 16.4% (n = 247) [8].
Additional subtypes of epithelia histology include: tubu-
lar, papillary, solid, large/giant cell, small cell, clear cell,
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signet cell, glandular, microcystic, myxoid, and adenoid
cystic [9,10].
Unlike some other tumors, there is no evidence for the
existence of a premalignant, non-invasive phase for MPM
[11]. This has made it difficult to determine which risk
factors and molecular changes are responsible for the ini-
tiation and further progression of MPM development.
However, through the use of cell culture, animal models,
and epidemiology, an active field of research and debate
has uncovered many players in MPM pathogenesis. The
first part of this review considers the genetic and molecu-
lar changes that have been identified in the development
of MPM. The second section will provide a more detailed
review of the known risk factors that may cause these
molecular changes and the controversies that surround
these risk factors.
Genetic and molecular processes in MPM
In the development of cancer, a cell acquires alterations in
gene expression and protein function that allow the cell to
surpass its normal growth limits. One way of acquiring
these alterations is through changes to the genome itself.
Abnormal karyotypes, often with extensive aneuploidy
and structural rearrangements, have been described for a
number of genetic loci in MPM [12,13]. The effects of
these mutations and additional effects from environmen-
tal risk factors have begun to explain how malignant mes-
othelioma cells form malignant tumors. Additional
Malignant pleural mesothelioma of sarcomatous type Figure 3
Malignant pleural mesothelioma of sarcomatous 
type. Sarcomatous MPM originates from the deep connec-
tive tissue of the mesothelial surface and resembles fibrosar-
coma. (Personal photo of Neragi-Mianoab).
Gross specimen of malignant pleural mesothelioma Figure 1
Gross specimen of malignant pleural mesothelioma. 
Presented here is an advanced case of malignant pleural mes-
othelioma encasing the lung and limiting lung compliance. Dif-
fuse growth into the lung parenchyma is also present. 
(Personal photo of Neragi-Mianoab).
Malignant pleural mesothelioma of epithelial type Figure 2
Malignant pleural mesothelioma of epithelial type. 
Epithelial MPM derives from the mesothelial cells and con-
sists of glands and tubules that resemble adenocarcinoma. 
Large spherical cells are arranged in solid masses and col-
umns mostly within lymphatics. There may also be glandular 
formation as demonstrated in this photograph. (Personal 
photo of Neragi-Mianoab).Journal of Carcinogenesis 2008, 7:3 http://www.carcinogenesis.com/content/7/1/3
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details about many of these pathways can be found in ear-
lier reviews [14-16].
Tumor Suppressors
Tumor suppressor genes (TSGs) play vital roles in regulat-
ing the cell cycle in response to DNA damage and other
stressors. The loss of TGS function is one of the funda-
mental events in tumorigenesis [17]. Loss of heterozygos-
ity (LOH) seems to be a consistent feature of MPMs,
which commonly lead to the loss and/or inactivation of
multiple TSGs. Pylkkanen et al. [18] demonstrated fre-
quent deletions at specific sites within chromosomal arms
1p, 3p, 6q, 9p, 13q, 15q, and 22q. p16/CDKN2A, p15/
CDKB2B and p14ARF at 9p21, FHIT gene at 3p and neu-
rofibromatosis 2 (NF2) at 22q12 are frequently altered
TSGs that account for some of these deleted sites in MPMs
[18-22]. Epigenetic methods may also contribute to TSG
inactivation. Promoter hypermethylation has been dem-
onstrated for p16/CDKN2A in MPM tumor samples and
cell lines, and for another TSG candidate RASSF1A located
at 3p21 in cell lines [23,24]. Wilms tumor suppressor
gene (WT1), another TSG associated with MPM, will be
discussed in the section on pediatric mesothelioma.
A surprising finding in mesothelioma research is the lack
of frequent mutations in the two most notorious TSGs:
p53 and pRb. Although p53 mutations have been found
in MPM cell lines [21,25], there is a general sense that the
contributions of p53 mutations in MPM pathogenesis are
minor [21,26-28]. However, the importance of p53 dereg-
ulation is well-recognized. p53 is essential for cell cycle
arrest in response to DNA damage and in genomic insta-
bility. When Vaslet et al. [29] induced mesothelioma
growth in heterozygous p53+/- mice with crocidolite asbes-
tos fibers, the mice that had lost the functioning allele of
p53 had shorter latent periods and more aggressive
tumors than the mice that still maintained one copy. Out-
side of this model, p53 function is more commonly
affected by mutations in upstream and downstream mem-
bers of the p53 pathways [16,25]. The most well-known
mechanism is the inactivation of p53's upstream regulator
p14ARF [14]. With the loss of p14ARF, the cell loses its
ability to inhibit MDM2. This allows MDM2 to inhibit
p53, which can no longer induce cell cycle arrest and
apoptosis.
The loss of pRb function occurs in a similar manner to
p53. This time p16/CDKN2A is mutated. In brief, p16/
CDKN2A can no longer inhibit cyclin-dependent kinases
4 and 6, which are responsible for the G1-S phase transi-
tion of the cell cycle. Left unchecked, these kinases can
phosphorylate and thereby inactivate pRb, which allows
an uncontrolled entry into S phase [14]. Homozygous
deletion of p16/CDKN2A has been reported in >70% of
malignant mesotheliomas, and has been associated with
poor prognosis [30,31]. In addition to proteins within the
p53 and pRb pathways, the role of a viral protein has also
been shown to inactivate these TSGs. The large tumor
antigen protein (SV40Tag) of the SV40 virus can bind to
and inactivate both p53 and pRb [32-37]. However, the
role of SV40 virus in mesothelioma is still a matter of
debate, as discussed below.
Not only must malignant tumors continue their growth,
but they must also be able to move and invade. A recent
paper by Poulikakos et al. [38] proposes a mechanism
through which merlin, the product of NF2, may help mes-
othelioma cells acquire this ability. Through the use of in
vitro assays, Poulikakos et al. [38] found that the re-expres-
sion of merlin in two human malignant mesothelioma
cell lines significantly decreased cell motility and inva-
sion. Furthermore, merlin may mediate its effects through
the phosphorylation of focal adhesion kinase. Further evi-
dence is needed in order to determine if merlin functions
in this particular way in vivo.
Oncogenes
While the loss of TSGs allows the cell to grow in light of
aberrant changes in cellular DNA and function, it is the
activation of oncogenes that inspires cell growth and pro-
liferation. AP-1 and β-catenin transcription factors are
implicated in MPM pathogenesis. The AP-1 family of tran-
scription factors is known for mediating a wide range of
processes including proliferation, apoptosis and transfor-
mation in response to a variety of stimuli [39]. The activa-
tion and expression of AP-1 proteins are regulated by
different mitogen-activated protein kinases (MAPK) [40].
Fra-1, a member of the Fos family of AP-1 transcription
factors, has been implicated in MPM pathogenesis.
Ramos-Nino et al. [41] found a high level of AP-1 DNA
binding activity and an increased expression of Fra-1 in
mesothelioma cell lines. In addition, rat mesothelial cells
exposed to either asbestos or epidermal growth factor
(EGF) showed an increase in Fra-1 expression. This
expression was abrogated when cells were pretreated with
an inhibitor to the MAPK, extracellular-signal-regulated
kinase (ERK). When mesothelioma cell lines were treated
with either the ERK inhibitor or were transfected with a
vector carrying a dominant negative fra-1, there was a
reversal of the transformed phenotype of the cells [41].
Previous work also examined the role of asbestos and the
EGF receptor in ERK activation [42]. Zanella et al. [42,43]
hypothesized that asbestos may activate the EGF receptor
itself or may also induce the ERK pathway through the for-
mation of reactive oxygen species. Hepatocyte growth fac-
tor (HGF) and signaling through its receptor, c-Met, may
also activate ERKs in addition to the Akt pathway [44].
Furthermore, the small tumor antigen (SV40tag) protein
of the SV40 virus may activate ERK. SV40tag is known to
inhibit protein phosphatase 2A (PP2A). Due to this inhi-Journal of Carcinogenesis 2008, 7:3 http://www.carcinogenesis.com/content/7/1/3
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bition, PP2A can no longer dephosphorylate and inacti-
vate members of the MAPK family [32,41].
The transcription factor β-catenin is regulated by an ubiq-
uitin ligase pathway. In the absence of Wnt signaling, gly-
cogen synthase kinase 3B (GSK3β) phosphorylates
adenomatous polyposis coli (APC) and axin, which
increases their affinity for β-catenin. GSK3β can then
phosphorylate  β-catenin, marking it for destruction.
When Wnt is present, GSK3β phosphorylation is inhib-
ited, allowing β-catenin to escape ubiquination, and enter
the nucleus where it can bind to T-cell factor/lymphoid-
enhancer factor (Tcf/Lef) transcription factor proteins
thereby activating transcription of downstream effectors
[45]. The role of this oncogenic pathway has been previ-
ously reviewed by Lee et al. [14] Here we briefly discuss
the concerns surrounding the activation of β-catenin in
MPM. It is interesting that activating mutations in the
GSK3β phosphorylation sites of β-catenin have not been
detected [46] since mutations in the p53 and pRb tumor
suppressors also do not appear to play an important role
in MPM pathogenesis as discussed above. Just as with
these TSGs, we may need to look to upstream regulators
in order to find our answer as to how β-catenin is acti-
vated. For example, an increase in disheveled expression
has been observed in patient samples and mesothelioma
cell lines, [47] and a lack of staining in some mesothelio-
mas for the C-terminus of APC has led to the hypothesis
that inactivating mutations of APC may be involved [46].
A group of upstream negative-regulators of the Wnt path-
way have also been implicated. Wnt inhibitory factor 1
(WIF-1) [48], Dickkopf-1 [49], and secreted frizzle-related
proteins (sFRP) [50,51] have the ability to inhibit Wnt sig-
naling at the level of cell membrane receptor activation.
Thus far, data has demonstrated a possible role for pro-
moter methylation in the inactivation of WIF-1 and sFRPs
[48,50], a mechanism also described for TSG inactivation.
Lee et al. [49] has also hypothesized that some of these
mediators may have a role outside of the canonical Wnt-
β-catenin pathway. Lastly, SV40tag may also be involved
in the activation of the Wnt pathway, in addition to its
role of ERK activation [32]. In this case, the inhibited
PP2A cannot inactivate the transcription factor β-catenin,
making entrance to the nucleus possible.
Landscapers
The role of growth factors in carcinogenesis has already
been suggested above in the case of MAPK pathway activa-
tion by EGF. Growth factors can stimulate proliferative
pathways through their contact with membrane receptors.
They may also play a role in the process of tumor invasion
and metastasis, which has been demonstrated by their
ability to stimulate chemotactic and/or chemokinetic
motility in mesothelioma cell lines [52]. Moreover, they
can act on stromal cells in order to provide an environ-
ment favorable to tumor growth. For example, endothe-
lial cells proliferate during the process of angiogenesis,
which supplies the growing tumor with necessary oxygen
and nutrients. Another important family of landscaper
genes is the matrix metalloproteases (MMPs), which help
to degrade the extracellular matrix that surrounds the
tumor [53-57]. This process is also important in angiogen-
esis as well as in tumor migration and invasion. Here we
also mention that the expression of cyclooxygenase 2
(COX-2) has been recognized as a prognostic factor in
MPM as reviewed elsewhere [15,16]. It is possible that
COX-2 may play a role in angiogenesis and/or resistance
to apoptosis [58].
Many growth factors, such as insulin-like growth factor-1
(IGF-1) [16,59], hepatocyte growth factor (HGF) [44,60],
basic fibroblast growth factor (b-FGF) [61], TNF-α [62],
EGF [14,63], VEGF [14,64-68] and platelet-derived
growth factor (PDGF) A and B [69], have been implicated
in the development and progression of malignant mes-
othelioma. Growth factors may come from a variety of
sources during the course of MPM pathogenesis such as
the surrounding lung parenchyma [70], macrophages
[62], and from the mesothelial cells themselves [44,62] in
response to a number of stimuli including inflammatory
cytokines [62,70], asbestos [62], and SV40 infection
[64,65]. Some of these stimuli may also induce ectopic
signaling through growth factor receptors without the
need for ligand stimulation [42] and/or activating muta-
tions of these receptors may result in signaling [44]. The
role of growth factors in oncogenesis has become a pro-
vocative subject in cancer therapy since the development
of cytotoxic drugs that target these growth factors offer
fresh potential for the treatment of mesothelioma [67,71].
Here we discuss the role of VEGF, HGF, and TNF-α in
more detail. Additional growth factors are reviewed else-
where [14-16].
VEGF is an angiogenic peptide, which is an independent
prognostic factor in MPM [66]. Higher VEGF levels were
found in the pleural effusions of patients with MPM com-
pared to its level in the effusions of patients with non-
malignant pleural disease [68]. While VEGF is a fairly spe-
cific angiogenic factor, it has also been shown to increase
the growth of mesothelioma cells in vitro [68]. The use of
antisense oligonucleotides (ODN) to inhibit the produc-
tion of both VEGF and VEGF-C slowed mesothelioma cell
growth. In addition, antibodies to VEGF receptor (VEGFR-
2) and VEGF-C receptor (VEGFR-3) had a synergistic effect
in inhibiting mesothelioma cell growth [67]. One mecha-
nism that may increase the production of VEGF in MPM is
SV40 infection. Production and release of VEGF was
greater in SV40Tag-positive MPM cells than in MPM cells
that did not show evidence of SV40 infection [65]. It
appears that this effect is mediated through more than justJournal of Carcinogenesis 2008, 7:3 http://www.carcinogenesis.com/content/7/1/3
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SV40Tag, since mesothelial cells transfected with the full
length SV40 genome produced higher levels of VEGF as
compared to cells transfected with SV40Tag only [65].
HGF has many possible roles in MPM pathogenesis. It
may stimulate morphological changes [64], promote cell
growth and migration [44,64] and induce angiogenesis by
itself or through an increase in the production of VEGF
[72]. Some of these effects may be mediated by down-
stream signaling via Akt and ERK pathways [44]. The
mechanisms by which HGF and its receptor are activated
are not fully understood. Cacciotti et al. proposes an
SV40-mediated activation that is dependent on SV40Tag
binding to pRb. The HGF that is produced in response to
SV40 infection signals through autocrine and paracrine
mechanisms [64]. HGF may also come from neighboring
lung tissue that has been damaged by asbestos exposure
and inflammation [70]. Lastly, signaling through c-Met
may be caused through activating mutations [44].
TNF-α may help to explain the survival of mesothelial
cells after exposure to asbestos [62]. Human mesothelial
cells are sensitive and often die after phagocytosis of
asbestos fibers [73]. The dilemma caused by this finding
is well stated by Yang et al. [62]: "How can asbestos cause
MM [malignant mesothelioma] if HM [human mesothe-
lial cells] exposed to asbestos die?" They show in vitro that
asbestos induces the expression of TNF-α and its receptor
in human mesothelial cells, and that cell survival may be
mediated by the NF-κB pathway downstream of receptor
activation. They also propose that other cells, macro-
phages in particular, may be important contributors of
TNF-α in vivo [62]. More research is needed in order to test
this hypothesis.
Apoptosis Genes
Apoptosis frequently occurs in response to signals from
outside the cell. For example, TNF-related apoptosis-
inducing ligand (TRAIL), Fas ligand and a lack of growth
factor stimulation may result in programmed cell death
[74]. However, it is a couple of intracellular mediators of
apoptosis that have thus far been implicated in MPM. The
over-expression of BCL-2 helps to protect the cell from
apoptosis as reviewed elsewhere [14-16]. MPM cells may
also be protected from apoptosis by the ectopic expression
of telomerase [75], and SV40 infection may be one way
mesothelial cells activate this protein [76]. In the absence
of telomerase, telomeres located at the terminal segments
of chromosomes shorten with each cell division. At first,
these segments protect the coding regions of chromo-
somal DNA from degradation. When the telomeres
become too short, apoptosis ensues. The activation of tel-
omerase allows MPM cells to escape this mechanism of
cell death and to perpetuate mutations that might have
otherwise been discarded in the normal process of "cell
aging."
Risk factors of MPM: Their contributions and 
controversies
Many risk factors have been identified as contributors to
MPM pathogenesis. Above, we began the discussion sur-
rounding the contribution of genetics, asbestos, and SV40
infection. Here we will complete our discussion of these
factors and further introduce concerns surrounding the
relationship of MPM to radiation and to the pediatric
population.
Asbestos Exposure
Asbestos' contribution to the pathogenesis of MPM is
multifaceted with effects ranging from direct to indirect,
genetic to molecular. Asbestos induces mutations in mes-
othelial cells. The more direct mechanism of injury
includes deposition of asbestos fiber in the pleura. Longer
fibers can penetrate deeply into parietal pleura and have a
high likelihood of causing cancer [77]. Asbestos fibers
may also damage the mitotic spindle of cells and thereby
disrupt mitosis, resulting in aneuploidy and DNA damage
[78,79]. In a less direct fashion, asbestos can lead to the
formation of reactive oxygen species (ROS). The produc-
tion of ROS can be catalyzed by the iron content of the fib-
ers or can occur through additional reactions on the fiber
surface [80,81]. Macrophages that have phagocytosed
asbestos fibers release ROS and lymphokines, which can
damage DNA and possibly suppress the immune system
[82,83]. Asbestos and/or the resulting ROS may also
directly activate cell-signaling pathways [42,43].
The response of mesothelial cells to asbestos and ROS is
an important factor in MPM pathogenesis. Above, we
described the possible role of TNF-α in protecting mes-
othelial cells from death after asbestos exposure [62]. The
ability to manage oxidative damage may be another
mechanism mesothelial cells use to protect themselves
[84]. Ferritin heavy chain (FHC) is a subunit of ferritin
involved in iron sequestration. Aung et al. [84] found that
when two mesothelioma cell lines were treated with
asbestos, the cells that expressed higher levels of FHC had
a smaller percentage increase in hydrogen peroxide gener-
ation and experienced less apoptosis as compared to cells
that expressed lower levels. In addition, polymorphisms
in some genes of important free radical scavenging
enzymes such as mitochondrial manganese superoxide
dismutase (MnSOD), glutathione-S-transferase M1 and
mEH have been associated with MPM [85,86].
The Asbestos Controversy: Which Fiber is Responsible?
The use of the single term "asbestos" to describe at least
five unique fibrous silicate minerals (see table 1) hides the
underlying controversy as to which fibers truly carry carci-Journal of Carcinogenesis 2008, 7:3 http://www.carcinogenesis.com/content/7/1/3
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nogenic potential. The asbestos fibers, with regard to their
bio-persistence and dimensional properties, have been
stratified into two main groups: serpentine fibers (mainly
chrysotile), and amphibole fibers (consisting of crocidol-
ite, tremolite, anthrophylite and amosite). Nearly 95% of
asbestos used internationally is chrysotile, and only 5% is
amosite and crocidolite [87], although these groups of fib-
ers are commonly found mixed together. New members
of the asbestos family and new fiber species have been
found to have carcinogenetic potential [88,89]. Exposure
to these fibers may help to explain why some communi-
ties experience a high incidence of MPM without any
known evidence of asbestos exposure [89].
The two different theories dealing with carcinogenicity of
asbestos fibers are the Amphibole Hypothesis and Stan-
ton's Theory. The Amphibole Hypothesis claims that only
amphibole fibers can cause cancer, since chrysotile fibers
are broken down and cleared too quickly to provoke car-
cinogenesis [90]. This is in contrast to amphibole fibers,
which persist in the body for a longer period of time as a
result of their durability and biopersistance [91]. The
Stanton Theory suggests that long and thin fibers (≥ 8
micrometer in length and ≤ 0.25 microm in width) are
strongly carcinogenic regardless of their physicochemical
nature [92], since they can penetrate further into the
pleura [77].
There is data that both supports and opposes these theo-
ries. In his recent reviews [93,94], Yarborough concludes
that the epidemiological evidence for the role of chrysotile
fibers in MPM pathogenesis is weak and that chrysotile
may not play a significant role in this disease process.
However, he does admit that a threshold for chrysotile
most likely exists though it has not yet been adequately
detected by epidemiological research [93]. Although Yar-
borough's conclusions mainly support the Amphibole
Hypothesis, they do not completely rule out a role for
chrysotile fibers in MPM pathogenesis. Conclusions con-
cerning the Stanton Hypothesis are also mixed. A recent
expert panel concluded that longer fibers have more carci-
nogenic potential [95] although an earlier review of ani-
mal and in vitro studies by Jaurand [96] did not find this
correlation. The role of the different fiber types and the
quantity of exposure necessary to cause MPM are still con-
troversial. The data are complicated by the variability in
study designs and definitions as well as by the role of
other risk factors such as genetics, industrial hygiene, and
concomitant smoking [96-99]. However, the general con-
sensus holds that longer fibers and amphibole fibers have
more carcinogenic potential than their shorter and chrys-
otile counterparts in regards to MPM.
Radiation
Recent advances in cancer treatment involve multimodal-
ity approaches that include surgery, chemotherapy, and
irradiation. Although these combined therapies increase
survival in certain types of cancer, they can also cause the
development of new malignancies [2,100,101]. Ionizing
radiation, in particular, has been shown to play an impor-
tant role in secondary benign and malignant tumors
[102,103]. Post-radiation malignant mesothelioma has
been reported after radiation therapy for breast cancer
[102,104,105], Hodgkin's disease [106], cervical cancer
[107]. Wilm's tumor [108-110], and seminoma [111]. In
order to rule out previous asbestos exposure as a risk fac-
tor in these cases, Wissman [112] measured the levels of
ferruginous bodies in the lung of a patient who developed
MPM after radiation for Hodgkin's disease. The lung tis-
sue showed 250 ferruginous bodies per gram of lung tis-
sue, which is consistent with no significant prior asbestos
exposure. In addition, Cavazza et al. [113] reviewed the
National Cancer Institute's SEER data for 30 patients who
developed malignant mesothelioma after radiation ther-
apy. According to Cahan's criteria, these cases of mesothe-
lioma may be considered as treatment-related post-
radiation mesothelioma or sarcoma [114]. Radiation
seems to contribute to MPM development in a small per-
centage of patients after radiation therapy. This low inci-
dence may be explained by a multifactorial cause of
secondary malignancies. In addition to radiation, expo-
sure to chemotherapy, genetic predisposition, environ-
mental cocarcinogens and other factors may be needed in
their development [115]. As the frequent use of radiation
therapy has raised concerns about future increases in the
incidence of these secondary malignancies [116-118],
future research to recognize these additional risk factors
may be useful in identifying and modifying the treatment
of patients who are likely to develop these secondary can-
cers.
SV40 virus
SV40 is a poliomavirus with double-stranded circular
DNA [33,119]. The virus has two regions, early and late.
The early region encodes SV40Tag, SV40tag, and 17 KT.
Table 1: Classification of asbestos fibers
Type Subtype Known Chemical Formula
Serpentine
Chrysotile Mg6Si4O10(OH)8
Amphibole
Crocidolite Na2(Fe3+)2(Fe2+)3Si8O22(OH)2
Tremolite Ca2Mg5Si8O22 (OH)2
Anthophyllite (Mg,Fe)7Si8O22(OH)2
Amosite
Actinolite Ca2(Mg, Fe)5Si8O22(OH)2
Fluoro-edenite
Erionite
ZeoliteJournal of Carcinogenesis 2008, 7:3 http://www.carcinogenesis.com/content/7/1/3
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The late region encodes structural proteins of the virus
[120]. Important roles of the early proteins in TSG, onco-
gene and growth factor regulation were described above.
Briefly, SV40Tag can bind to and inhibit p53 and pRb
TSGs, and SV40tag has been shown to inhibit PP2A,
which may lead to the activation of Wnt and ERK signal-
ing pathways. SV40 infection may also increase autocrine
and paracrine signaling through a variety of growth factor
pathways and induce the expression of telomerase [32].
Another possible role of SV40 in MPM that was not stated
above is that SV40 infection may increase the transcrip-
tion and activation of Notch-1, which may have an impor-
tant role in mesothelial cell transformation and
proliferation [121]. Lastly, SV40 has been hypothesized to
work as a cocarcinogen with asbestos [73,122-125]. SV40
may provide another mechanism by which mesothelial
cells escape asbestos' cytotoxic effects [122]. Cacciotti et
al. [122] found that mesothelial and mesothelioma cells
infected with SV40 were more resistant to asbestos treat-
ment. They concluded that this effect may be mediated by
the activation of the phosphatidylinositol-3 kinase/Akt
(PI3K/Akt) pathway. This pathway may become activated
downstream of SV40's ability to induce growth factor sig-
naling pathways or through other mechanisms. They pro-
vided in vivo evidence from mesothelioma samples. 10
out of 11 tumors with detectable SV40Tag expression also
stained positively for activated Akt. After helping mes-
othelial cells survive asbestos exposure, SV40 may also
work with asbestos to cause DNA damage [125] and to
transform cells [73,122,124]. When Bocchetta et al. [73]
expressed SV40Tag and SV40tag in human mesothelial
and fibroblast cells, cells that had been treated with asbes-
tos showed a larger number of transformed foci as com-
pared to cells that only expressed SV40.
Controversy about SV40: Does SV40 really play a role?
Not only does the above data supply strong mechanistic
support for the role of SV40 infection in MPM pathogen-
esis, but in vitro experiments have also demonstrated a
high susceptibility of mesothelial cells to develop stable
infections by SV40 as compared to human fibroblasts,
which quickly lyse after only semipermissive infection
[73]. Despite this collection of mainly in vitro data, a role
of SV40 infection in MPM pathogenesis has not been
established due to the conflicting results of epidemiologi-
cal studies.
From 1955 to 1963, the polio vaccine supplied to the
United States, Canada, Europe, Asia and Africa was con-
taminated with SV40. Furthermore, the possibility of hor-
izontal transmission may have enlarged this exposure
[32]. Many studies [123,126-130] have found evidence of
SV40 infection. A meta-analysis conducted by Vilchez
[131] reviewed molecular, pathological, and clinical data
from 1,793 cancer patients. He concluded that there is sig-
nificant data to support a role for SV40 infection in
human brain cancers, bone cancers, malignant mesotheli-
oma, and non-Hodgkin's lymphoma. However, whether
these results can be attributed to polio virus contamina-
tion is not completely clear [128,129,132,133]. Popula-
tions in Finland and Turkey were not exposed to the
contaminated vaccine. In these cases, SV40 contamina-
tion was not observed in MPM as would be expected if the
source of infection was primarily vaccination. On the
other hand, Engels et al. [134] reported that although a
contaminated poliovirus vaccine was administered to
most children in Denmark from 1955 to 1961, there was
no increase in malignant mesothelioma incidence [134].
Additional studies argue against the significance of SV40
infection [135,136]. In a study by Manfredi et al. [135],
SV40Tag DNA was not detectable in tumor tissue of 69
mesothelioma patients. SV40Tag protein was also unde-
tectable in tumor samples and mesothelioma cell lines by
immunohistochemistry. Perhaps the standardization of
SV40-detection techniques and more comprehensive
studies will determine if SV40 will be a worthwhile target
for preventative measures in the future [32].
Pediatric mesothelioma, familial cases and genetic 
predisposition
Mesothelioma is very rare in childhood with an estimated
2%–5% of all cases occurring in the first two decades of
life. The diagnosis may be challenging because of its rarity
and its pathologic similarities to other papillary or spindle
cell neoplasms in the pediatric age group [137,138]. To
date, little is known about the pathogenesis of MPM in
children. Frair et al. [139] reviewed the risk factors in a
series of 80 pediatric patients with malignant mesotheli-
oma. Only four of the 80 children had exposure to known
risk factors (two had history of exposure to asbestos, one
had received radiation therapy, and one was exposed to
isoniazid in utero). A causal relationship between malig-
nant mesothelioma and asbestos exposure, radiation,
and/or isoniazid could not be established. As far as asbes-
tos is concerned, the long latency of asbestos-related mes-
othelioma makes a role for this risk factor in pediatric
MPM unlikely [140,141] unless the natural history of
asbestos-related cancer in children is very aggressive and
rapidly progresses [140].
Pediatric and familial cases may open an avenue for the
study of genetic contributions to MPM. Small case studies
have found that pediatric patients with Wilm's tumor who
were treated with radiation may be at an increased risk for
mesothelioma [110,142]. This risk may represent a role of
WT1 as a TSG in MPM pathogenesis. However, this pic-
ture is complicated by data that reports a lack of inactivat-
ing mutations in MPM [143-145]. Also, one study has
reported a de novo activating-mutation in WT1 in a 45-
year old woman with a perotineal mesothelioma [145],Journal of Carcinogenesis 2008, 7:3 http://www.carcinogenesis.com/content/7/1/3
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and many studies have demonstrated the expression of
WT1 in mesothelioma as reviewed by Whitson et al. [16].
It may be possible that the WT1 plays different roles in
pediatric versus adult mesotheliomas, or that the associa-
tion of Wilm's tumor with mesothelioma is confounded
by the exposure to radiation and other risk factors. The
study of pediatric patients who have not been exposed to
known risk factors may provide a key opportunity to eval-
uate WT1 involvement in MPM in addition to the role of
other genetic contributors.
Familial cases also support the role of genetic predisposi-
tion to MPM [146,147]. However, the interpretation of
these studies may be complicated by the presence of com-
mon environmental exposures. Ascoli et al. [146] found
that most of the familial cases in their study had been
exposed to asbestos. One might conclude that this com-
mon exposure outweighs any contribution of genetics. On
the other hand, these cases provide a resource to examine
genetics-asbestos interactions in MPM pathogenesis, and
may help to explain why less than 10% of people exposed
to asbestos develop mesothelioma [130]. Already, various
studies have begun to apply modern genetic association
techniques to the study of mesothelioma
[31,85,86,148,149]. However more rigorous studies with
larger sample sizes will be needed in order to make the
most out of these techniques. Ohar et al. [150] has also
offered other demographic information that may be taken
into consideration when planning and analyzing genetic
studies.
Conclusion
MPM has a complex etiology in which asbestos, ionizing
radiation, viruses, genetic factors, and even diet [151] may
act alone or in concert to activate the molecular processes
necessary for carcinogenesis. A multi-step process is sup-
ported by the observation that numerous chromosomal
deletions accumulate in most malignant mesotheliomas,
many of which result in the loss and/or inactivation of
TSGs [18,22]. However, uncovering the temporality of
these steps has been difficult. Although many experimen-
tal techniques have been employed, the study of MPM is
complicated by its late stage at diagnosis and its rarity. The
long latency between asbestos exposure and MPM diagno-
sis exemplifies these problems. It is unclear if the time lag
between asbestos exposure and diagnosis reflects a slow-
growing tumor after early genetic mutations, or if the
accumulation of genetic changes reaches a threshold of
malignant transformation [11] since the late stage of diag-
nosis makes it difficult to determine the temporality of
various genetic and molecular events. In addition, the
long latency and the rarity make asbestos-induced MPM a
poor candidate for comprehensive cohort studies.
Through the application of innovative animal models
[21,124,152], in vitro studies, and epidemiology, we may
be able to gain a better understanding of which risk factors
and molecular targets are the most important for future
preventative and therapeutic measures.
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